CTLT
Catalent, Inc. (acquired by Novo Holdings; no CTLT listing)
Is CTLT Halal?
Novo Holdings completed Catalent's acquisition in December 2024 and CTLT became private; pharmaceutical-manufacturing analysis remains qualitative.
What You Should Know
CTLT is a preserved Catalent route. Novo Holdings completed the acquisition on December 18, 2024, and Catalent became a private company. Drug-development and contract-manufacturing services remain generally permissible in principle, while ingredients, excipients, customer portfolios and clinical materials require qualitative review; no current standalone CTLT quantitative screen is applicable.
⚠️ Concerns
- •CTLT became private after the December 2024 acquisition
- •Drug ingredients, excipients and manufacturing processes
- •Customer product portfolio and clinical materials
- •CTLT is a preserved Novo-acquisition alias; the URL is unchanged
Current quantitative Sharia screen
Based on issuer-status figures for the period ended 2024-12-18; calculated 2026-07-15.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated because Catalent became privately held in December 2024.
- Financial
- Not calculated
- Overall
- Not calculated
No current standalone Catalent financial statement is available.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated for the delisted CTLT security.
- Financial
- Not calculated
- Overall
- Not calculated
CTLT has no current public-market price or market-cap series.
Business-activity disclosure
Catalent historically provided drug-development, delivery and contract-manufacturing services, generally permissible in principle. Product ingredients, customer portfolios and manufacturing uses remain qualitative; CTLT is no longer publicly traded.
Limitation: No current standalone public-company balance sheet, revenue statement or market-cap series is available after Novo Holdings's acquisition.
Purification
No current standalone CTLT issuer income is available for purification.
Inputs, assumptions and primary sources
- Novo Holdings completed its acquisition of Catalent on December 18, 2024; CTLT ceased public trading and became private.
- No Novo Holdings or private-company figures are substituted for a standalone CTLT screen, so numerical ratios are intentionally not calculated.
- The route and existing pharmaceutical-development and manufacturing qualitative analysis are preserved.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →